Key facts
- It has raised $89.5M; the latest was Early Stage VC ($22.0M) in Nov 2025.
- Notable investors include Sequoia Capital, F-Prime Capital, Qiming Venture Partners, Eight Roads, OrbiMed — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Tandem AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Tandem AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tandem AI
Developer of an advanced network platform designed to lower barriers to entry to the most advanced tools in drug discovery. The company's platform integrates proprietary AI-driven, high-performance computation with efficient, large-scale in-house wet lab operations, enabling the global scientific community to increase the speed of drug discovery and deliver cost-effective opportunities.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 300
- Website
- tandemai.com/
- Ownership
- Privately Held (backing)
Tandem AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tandem AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tandem AI in its N-PORT filings yet. We sweep new filings monthly.